EPO and myelodysplastic syndrome: The results of two large, multicenter, randomized, double‐blind, placebo‐controlled clinical trials evaluating erythropoietin (EPO) or darbepoetin versus placebo in low‐risk MDS (EPOANE3021 [NCT01381809] and ARCADE [NCT01362140]) have been finalized and published [14, 15].